Quest Diagnostics Completes Acquisition of Cleveland Heartlab

Quest Diagnostics (NYSE: DGX) today announced that it has completed its previously announced acquisition of Cleveland HeartLab. Quest will establish a national center of excellence focused on heart disease diagnostics within Cleveland HeartLab's existing 25,000 square-foot clinical laboratory facility in Cleveland.

The acquisition combines the expertise of Cleveland HeartLab's personalized evaluation of heart disease risk based on inflammation and other markers with Quest's Cardio IQ® lipid particle analysis and genetic and metabolic testing leadership. Heart disease is the number one cause of death in the United States. Conventional laboratory tests to assess cardiovascular disease, such as cholesterol panels, may not identify risk in all patients. New inflammation, genetic and other biomarkers may help physicians identify at-risk patients and guide treatment protocols to improve outcomes.Quest Diagnostics (NYSE: DGX) today announced that it has completed its previously announced acquisition of Cleveland HeartLab. Quest will establish a national center of excellence focused on heart disease diagnostics within Cleveland HeartLab's existing 25,000 square-foot clinical laboratory facility in Cleveland.The acquisition combines the expertise of Cleveland HeartLab's personalized evaluation of heart disease risk based on inflammation and other markers with Quest's Cardio IQ® lipid particle analysis and genetic and metabolic testing leadership. Heart disease is the number one cause of death in the United States. Conventional laboratory tests to assess cardiovascular disease, such as cholesterol panels, may not identify risk in all patients. New inflammation, genetic and other biomarkers may help physicians identify at-risk patients and guide treatment protocols to improve outcomes.

Congratulations to the team at Cleveland Heartlab! Read more about the finalized acquisition here